APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Temozolomide Capsules

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Temozolomide Capsules Market Outlook and Growth Opportunities 2026

Report ID 174040120427 December 2025194 pages

Choose your research edition.

Industry ResearchTemozolomide Capsules Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Temozolomide Capsules Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Temozolomide Capsules Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Temozolomide Capsules Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Temozolomide Capsules Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Temozolomide Capsules market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Temozolomide Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Temozolomide Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Temozolomide Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Temozolomide Capsules market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Temozolomide Capsules market include Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories, Luye Pharma Group, Merck Sharp & Dohme B.V., Organon LLC, Santen Pharmaceutical Co.,Ltd., Hybio Pharmaceutical, Hengrui Medicine and Mylan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Temozolomide Capsules market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Temozolomide Capsules and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Temozolomide Capsules revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Temozolomide Capsules market.

Temozolomide Capsules Segment by Company

Boehringer Ingelheim International GmbH

Dr. Reddy's Laboratories

Luye Pharma Group

Merck Sharp & Dohme B.V.

Organon LLC

Santen Pharmaceutical Co.,Ltd.

Hybio Pharmaceutical

Hengrui Medicine

Mylan Pharmaceuticals

Teva Pharmaceutical Industries

Temozolomide Capsules Segment by Type

20mg

100mg

Temozolomide Capsules Segment by Application

Hospital

Clinic

Others

Temozolomide Capsules Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Temozolomide Capsules status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Temozolomide Capsules key companies, revenue, market share, and recent developments.

3. To split the Temozolomide Capsules breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Temozolomide Capsules market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Temozolomide Capsules significant trends, drivers, influence factors in global and regions.

6. To analyze Temozolomide Capsules competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Temozolomide Capsules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Temozolomide Capsules and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Temozolomide Capsules.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Temozolomide Capsules industry.

Chapter 3: Detailed analysis of Temozolomide Capsules company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Temozolomide Capsules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Temozolomide Capsules in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Temozolomide Capsules Industry Trends Table 2. Temozolomide Capsules Industry Drivers Table 3. Temozolomide Capsules Industry Opportunities and Challenges Table 4. Temozolomide Capsules Industry Restraints Table 5. Global Temozolomide Capsules Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Temozolomide Capsules Revenue Share by Company (2021-2026) Table 7. Global Temozolomide Capsules Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Temozolomide Capsules Key Company Manufacturing Base & Headquarters Table 9. Global Temozolomide Capsules Company, Product Type & Application Table 10. Global Temozolomide Capsules Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Temozolomide Capsules by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 20mg Table 15. Significant Companies of 100mg Table 16. Global Temozolomide Capsules Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Temozolomide Capsules Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Temozolomide Capsules Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Temozolomide Capsules Sales Value Share by Type (2021-2026) Table 20. Global Temozolomide Capsules Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Temozolomide Capsules Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Temozolomide Capsules Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Temozolomide Capsules Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Temozolomide Capsules Sales Value Share by Application (2021-2026) Table 28. Global Temozolomide Capsules Sales Value Share by Application (2027-2032) Table 29. Global Temozolomide Capsules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Temozolomide Capsules Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Temozolomide Capsules Sales Value Share by Region (2021-2026) Table 32. Global Temozolomide Capsules Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Temozolomide Capsules Sales Value Share by Region (2027-2032) Table 34. Global Temozolomide Capsules Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Temozolomide Capsules Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Temozolomide Capsules Sales Value Market Share by Country (2021-2026) Table 37. Global Temozolomide Capsules Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Temozolomide Capsules Sales Value Market Share by Country (2027-2032) Table 39. Boehringer Ingelheim International GmbH Company Information Table 40. Boehringer Ingelheim International GmbH Business Overview Table 41. Boehringer Ingelheim International GmbH Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Boehringer Ingelheim International GmbH Temozolomide Capsules Product Portfolio Table 43. Boehringer Ingelheim International GmbH Recent Development Table 44. Dr. Reddy's Laboratories Company Information Table 45. Dr. Reddy's Laboratories Business Overview Table 46. Dr. Reddy's Laboratories Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Dr. Reddy's Laboratories Temozolomide Capsules Product Portfolio Table 48. Dr. Reddy's Laboratories Recent Development Table 49. Luye Pharma Group Company Information Table 50. Luye Pharma Group Business Overview Table 51. Luye Pharma Group Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Luye Pharma Group Temozolomide Capsules Product Portfolio Table 53. Luye Pharma Group Recent Development Table 54. Merck Sharp & Dohme B.V. Company Information Table 55. Merck Sharp & Dohme B.V. Business Overview Table 56. Merck Sharp & Dohme B.V. Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck Sharp & Dohme B.V. Temozolomide Capsules Product Portfolio Table 58. Merck Sharp & Dohme B.V. Recent Development Table 59. Organon LLC Company Information Table 60. Organon LLC Business Overview Table 61. Organon LLC Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Organon LLC Temozolomide Capsules Product Portfolio Table 63. Organon LLC Recent Development Table 64. Santen Pharmaceutical Co.,Ltd. Company Information Table 65. Santen Pharmaceutical Co.,Ltd. Business Overview Table 66. Santen Pharmaceutical Co.,Ltd. Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Santen Pharmaceutical Co.,Ltd. Temozolomide Capsules Product Portfolio Table 68. Santen Pharmaceutical Co.,Ltd. Recent Development Table 69. Hybio Pharmaceutical Company Information Table 70. Hybio Pharmaceutical Business Overview Table 71. Hybio Pharmaceutical Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Hybio Pharmaceutical Temozolomide Capsules Product Portfolio Table 73. Hybio Pharmaceutical Recent Development Table 74. Hengrui Medicine Company Information Table 75. Hengrui Medicine Business Overview Table 76. Hengrui Medicine Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Hengrui Medicine Temozolomide Capsules Product Portfolio Table 78. Hengrui Medicine Recent Development Table 79. Mylan Pharmaceuticals Company Information Table 80. Mylan Pharmaceuticals Business Overview Table 81. Mylan Pharmaceuticals Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Mylan Pharmaceuticals Temozolomide Capsules Product Portfolio Table 83. Mylan Pharmaceuticals Recent Development Table 84. Teva Pharmaceutical Industries Company Information Table 85. Teva Pharmaceutical Industries Business Overview Table 86. Teva Pharmaceutical Industries Temozolomide Capsules Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Teva Pharmaceutical Industries Temozolomide Capsules Product Portfolio Table 88. Teva Pharmaceutical Industries Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Temozolomide Capsules Product Image Figure 2. Global Temozolomide Capsules Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Temozolomide Capsules Market Size (2021-2032) & (US$ Million) Figure 4. Global Temozolomide Capsules Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 20mg Image Figure 8. 100mg Image Figure 9. Global Temozolomide Capsules Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Temozolomide Capsules Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Temozolomide Capsules Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Temozolomide Capsules Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Temozolomide Capsules Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Temozolomide Capsules Sales Value Share by Application (2021-2032) Figure 18. Global Temozolomide Capsules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Temozolomide Capsules Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Temozolomide Capsules Sales Value (2021-2032) & (US$ Million) Figure 21. North America Temozolomide Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Temozolomide Capsules Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Temozolomide Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Temozolomide Capsules Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Temozolomide Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Temozolomide Capsules Sales Value (2021-2032) & (US$ Million) Figure 27. South America Temozolomide Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Temozolomide Capsules Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Temozolomide Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Temozolomide Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • 20mg
  • 100mg
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories
  • Luye Pharma Group
  • Merck Sharp & Dohme B.V.
  • Organon LLC
  • Santen Pharmaceutical Co.,Ltd.
  • Hybio Pharmaceutical
  • Hengrui Medicine
  • Mylan Pharmaceuticals
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Temozolomide Capsules Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Temozolomide Capsules Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Temozolomide Capsules Market Dynamics
  1. 2.1 Temozolomide Capsules Industry Trends
  2. 2.2 Temozolomide Capsules Industry Drivers
  3. 2.3 Temozolomide Capsules Industry Opportunities and Challenges
  4. 2.4 Temozolomide Capsules Industry Restraints
3 Temozolomide Capsules Market by Company
  1. 3.1 Global Temozolomide Capsules Company Revenue Ranking in 2025
  2. 3.2 Global Temozolomide Capsules Revenue by Company (2021-2026)
  3. 3.3 Global Temozolomide Capsules Company Ranking (2024-2026)
  4. 3.4 Global Temozolomide Capsules Company Manufacturing Base and Headquarters
  5. 3.5 Global Temozolomide Capsules Company Product Type and Application
  6. 3.6 Global Temozolomide Capsules Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Temozolomide Capsules Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Temozolomide Capsules Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Temozolomide Capsules Market by Type
  1. 4.1 Temozolomide Capsules Type Introduction
  2. 4.1.1 20mg
  3. 4.1.2 100mg
  4. 4.2 Global Temozolomide Capsules Sales Value by Type
  5. 4.2.1 Global Temozolomide Capsules Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Temozolomide Capsules Sales Value by Type (2021-2032)
  7. 4.2.3 Global Temozolomide Capsules Sales Value Share by Type (2021-2032)
5 Temozolomide Capsules Market by Application
  1. 5.1 Temozolomide Capsules Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Temozolomide Capsules Sales Value by Application
  6. 5.2.1 Global Temozolomide Capsules Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Temozolomide Capsules Sales Value by Application (2021-2032)
  8. 5.2.3 Global Temozolomide Capsules Sales Value Share by Application (2021-2032)
6 Temozolomide Capsules Regional Value Analysis
  1. 6.1 Global Temozolomide Capsules Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Temozolomide Capsules Sales Value by Region (2021-2032)
  3. 6.2.1 Global Temozolomide Capsules Sales Value by Region: 2021-2026
  4. 6.2.2 Global Temozolomide Capsules Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Temozolomide Capsules Sales Value (2021-2032)
  7. 6.3.2 North America Temozolomide Capsules Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Temozolomide Capsules Sales Value (2021-2032)
  10. 6.4.2 Europe Temozolomide Capsules Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Temozolomide Capsules Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Temozolomide Capsules Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Temozolomide Capsules Sales Value (2021-2032)
  16. 6.6.2 South America Temozolomide Capsules Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Temozolomide Capsules Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Temozolomide Capsules Sales Value Share by Country, 2025 VS 2032
7 Temozolomide Capsules Country-level Value Analysis
  1. 7.1 Global Temozolomide Capsules Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Temozolomide Capsules Sales Value by Country (2021-2032)
  3. 7.2.1 Global Temozolomide Capsules Sales Value by Country (2021-2026)
  4. 7.2.2 Global Temozolomide Capsules Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Temozolomide Capsules Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Temozolomide Capsules Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Temozolomide Capsules Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim International GmbH
  2. 8.1.1 Boehringer Ingelheim International GmbH Company Information
  3. 8.1.2 Boehringer Ingelheim International GmbH Business Overview
  4. 8.1.3 Boehringer Ingelheim International GmbH Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim International GmbH Temozolomide Capsules Product Portfolio
  6. 8.1.5 Boehringer Ingelheim International GmbH Recent Developments
  7. 8.2 Dr. Reddy's Laboratories
  8. 8.2.1 Dr. Reddy's Laboratories Company Information
  9. 8.2.2 Dr. Reddy's Laboratories Business Overview
  10. 8.2.3 Dr. Reddy's Laboratories Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dr. Reddy's Laboratories Temozolomide Capsules Product Portfolio
  12. 8.2.5 Dr. Reddy's Laboratories Recent Developments
  13. 8.3 Luye Pharma Group
  14. 8.3.1 Luye Pharma Group Company Information
  15. 8.3.2 Luye Pharma Group Business Overview
  16. 8.3.3 Luye Pharma Group Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Luye Pharma Group Temozolomide Capsules Product Portfolio
  18. 8.3.5 Luye Pharma Group Recent Developments
  19. 8.4 Merck Sharp & Dohme B.V.
  20. 8.4.1 Merck Sharp & Dohme B.V. Company Information
  21. 8.4.2 Merck Sharp & Dohme B.V. Business Overview
  22. 8.4.3 Merck Sharp & Dohme B.V. Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Sharp & Dohme B.V. Temozolomide Capsules Product Portfolio
  24. 8.4.5 Merck Sharp & Dohme B.V. Recent Developments
  25. 8.5 Organon LLC
  26. 8.5.1 Organon LLC Company Information
  27. 8.5.2 Organon LLC Business Overview
  28. 8.5.3 Organon LLC Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Organon LLC Temozolomide Capsules Product Portfolio
  30. 8.5.5 Organon LLC Recent Developments
  31. 8.6 Santen Pharmaceutical Co.,Ltd.
  32. 8.6.1 Santen Pharmaceutical Co.,Ltd. Company Information
  33. 8.6.2 Santen Pharmaceutical Co.,Ltd. Business Overview
  34. 8.6.3 Santen Pharmaceutical Co.,Ltd. Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Santen Pharmaceutical Co.,Ltd. Temozolomide Capsules Product Portfolio
  36. 8.6.5 Santen Pharmaceutical Co.,Ltd. Recent Developments
  37. 8.7 Hybio Pharmaceutical
  38. 8.7.1 Hybio Pharmaceutical Company Information
  39. 8.7.2 Hybio Pharmaceutical Business Overview
  40. 8.7.3 Hybio Pharmaceutical Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hybio Pharmaceutical Temozolomide Capsules Product Portfolio
  42. 8.7.5 Hybio Pharmaceutical Recent Developments
  43. 8.8 Hengrui Medicine
  44. 8.8.1 Hengrui Medicine Company Information
  45. 8.8.2 Hengrui Medicine Business Overview
  46. 8.8.3 Hengrui Medicine Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Medicine Temozolomide Capsules Product Portfolio
  48. 8.8.5 Hengrui Medicine Recent Developments
  49. 8.9 Mylan Pharmaceuticals
  50. 8.9.1 Mylan Pharmaceuticals Company Information
  51. 8.9.2 Mylan Pharmaceuticals Business Overview
  52. 8.9.3 Mylan Pharmaceuticals Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Pharmaceuticals Temozolomide Capsules Product Portfolio
  54. 8.9.5 Mylan Pharmaceuticals Recent Developments
  55. 8.10 Teva Pharmaceutical Industries
  56. 8.10.1 Teva Pharmaceutical Industries Company Information
  57. 8.10.2 Teva Pharmaceutical Industries Business Overview
  58. 8.10.3 Teva Pharmaceutical Industries Temozolomide Capsules Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Industries Temozolomide Capsules Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Industries Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst